NEWSWIRETODAY Press Release & Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Agency / Source: Bio-Rad Laboratories, Inc.

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

MRSASelect - Rapid Screening of MRSA - Bio-Rad Laboratories, Inc. announced FDA clearance for faster interpretation time of its existing MRSASelect™ test, a chromogenic medium that is used for the rapid screening of MRSA - Bio-Rad.com
MRSASelect - Rapid Screening of MRSA

 

NewswireTODAY - /newswire/ - Hercules, CA, United States, 2009/07/14 - Bio-Rad Laboratories, Inc. announced FDA clearance for faster interpretation time of its existing MRSASelect™ test, a chromogenic medium that is used for the rapid screening of MRSA - Bio-Rad.com. AMEX: BIO; BIOb

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Bio-Rad Laboratories, Inc., a multinational manufacturer and distributor of life science research and clinical diagnostic products, today announced FDA clearance for faster interpretation time of its existing MRSASelect™ test, a chromogenic medium that is used for the rapid screening of MRSA (methicillin-resistant Staphylococcus aureus). With high sensitivity and specificity as well as rapid and direct identification, the MRSASelect test can now identify MRSA carriers in as little as 18 hours. Bio-Rad received FDA clearance in the U.S. to market its MRSASelect test with the new interpretation time in June. The test was originally introduced in the U.S. in October 2007.

MRSA is an infectious bacterial strain that is resistant to antibiotics such as penicillin and methicillin. Most MRSA infections occur in hospitals or other healthcare settings. Individuals can become carriers of MRSA by physical contact with the organism or inhalation of it. To prevent transmission, the goal is to quickly identify and separate carriers. The MRSASelect test can speed up this process.

“The improved detection time of MRSASelect provides hospitals with the ability to report results earlier and allows a faster implementation of appropriate infection control,” said John Goetz, Bio-Rad Vice President and Group Manager Clinical Diagnostics. “This is key in reducing hospital stays and to minimizing the spread of this pathogen.”

About Bio-Rad
Bio-Rad Laboratories, Inc. (bio-rad.com) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs over 6,300 people globally and had revenues approaching $1.5 billion in 2007.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the “Risk Factors ” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2007, as updated by subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc. disclaims any obligation to update these forward-looking statements.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Bio-Rad Laboratories, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


MRSASelect - Rapid Screening of MRSA

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Christina L. Marshall - Bio-Rad.com 
510-741-5731 christina_marshall[.]bio-rad.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Bio-Rad Laboratories, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Bio-Rad Laboratories, Inc. / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Novotech Earns Frost & Sullivan’s 2025 Global Company of the Year Recognition for Excellence in Biotech Clinical Research Services
Ono Pharmaceutical and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
NEC and Chugai Pharmaceutical Use AI to Potentially Enhance Cancer Treatment
BASF Strengthens its Commitment to the Biopharma and Pharmaceutical Ingredients Industries through A New Investment in North America
ONO PHARMA Presents Positive Results from Pivotal Trial in U.S. Patients with Relapsed or Refractory PCNSL At 2025 ASCO Annual Meeting
SCHOTT Pharma Expands Ready-to-use Portfolio with Sterile 1.5 ml Cartridge
Ono Commences Research Collaboration with Jorna Therapeutics to Generate Novel RNA Editing Therapeutics
SCHOTT Pharma Opens Production Facility in Serbia to Strengthen Competitiveness in Europe
NEC Has Developed Technologies that Enable A Secure Workflow for Personalized Cancer Vaccines and Has Proven their Capabilities
BASF Aroma Ingredients Innovates with Two New Isobionics® Biotech Flavor Ingredients
Federal Government Invests .9 Million in STEMCELL Technologies Canada, Inc.
Ono Enters into License Agreement with Ionis Pharmaceuticals for Sapablursen for the Treatment of Polycythemia Vera
Boehringer Ingelheim Partners with Veeva to Launch ‘One Medicine Platform’
U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)
U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab & hyaluronidase-nvhy) Injection

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow, Inc.

Visit Vendor Velocity





 
  ©2005-2025 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)